Improving economic conditions and a more favorable regulatory environment give Goldman Sachs catalysts to benefit from in the ...

Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, Ratings reports. The firm currently has $45.00 ...

China is starting to see a rebound in M&As as government stimulus measures start to bear fruit and pressure from Donald Trump ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

CSL and Cochlear are two of Australia’s blue-chip healthcare stocks, stalwarts of many investors portfolios, whereas Pro ...

New orders also cascaded 16.4 points lower, though were still positive at 17.8. Barclays downgraded Moderna shares to equal weight from overweight, citing heightened policy uncertainties and limited ...

Investors seeking to outperform the market should focus their stock-picking efforts on volatile names in the consumer ...

Please be advised, today's conference is being recorded. I would now like to hand the conference over to your speaker today, Lavina Talukdar. Please go ahead. Thank you, Kevin. Good morning, everyone, ...

Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...

Shares of Roku Inc (NASDAQ:ROKU) are up 14.5% in premarket trading, after the streaming giant shared smaller-than-expected losses for the fourth quarter as well as a revenue beat. The company also ...

The Hang Seng Tech Index jumped 5.6% to a three-year high at close, bringing the week's advance to 7.3% and recording a fifth consecutive week of gains. The rally was helped after a Reuters report ...

Moderna is set to release its fourth-quarter earnings on Friday before the opening bell. Here's a look at what to expect in ...